Charles Schwab Investment Management Inc. Purchases 177,836 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Charles Schwab Investment Management Inc. raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 899,175 shares of the company’s stock after purchasing an additional 177,836 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $16,203,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. UMB Bank n.a. increased its stake in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co increased its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares in the last quarter. Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $52,000. Claro Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $52,000. Finally, GAMMA Investing LLC increased its stake in Teva Pharmaceutical Industries by 105.7% in the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after purchasing an additional 1,741 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $17.33 on Friday. Teva Pharmaceutical Industries Limited has a 52 week low of $9.35 and a 52 week high of $19.31. The firm has a market cap of $19.63 billion, a price-to-earnings ratio of -20.39, a P/E/G ratio of 1.06 and a beta of 0.79. The firm’s 50-day simple moving average is $17.54 and its 200 day simple moving average is $17.38. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.